Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
Clinical & Experimental Allergy2020Vol. 50(3), pp. 364–371
Citations Over TimeTop 10% of 2020 papers
Mehran Alizadeh Aghdam, Edward F. Knol, Mignon van den Elzen, Constance den Hartog Jager, Harmieke van Os‐Medendorp, André C. Knulst, Henny G. Otten, Heike Röckmann
Abstract
FcεRI expression on basophils decreased rapidly, while anti-IgE-induced degranulation significantly increased due to omalizumab treatment in patients with CSU, persisting at least for 3 months after stopping the treatment. None of the markers were able to predict the effectiveness of treatment. Whether basophils play a role in omalizumab responsiveness in CSU remains unclear.
Related Papers
- → EFFECT OF OMALIZUMAB ON PATIENTS WITH CHRONIC URTICARIA: ISSUES WITH THE DETERMINATION OF AUTOIMMUNE URTICARIA(2008)12 cited
- → OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA(2008)9 cited
- → The Potential Role of Omalizumab in the Treatment of Chronic Urticaria(2014)3 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)
- → 269 Refractory Chronic Urticaria Treated with Omalizumab(2012)